Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

‘Today Regeneron have issued a statement announcing a pause in recruitment of COVID-19 patients with high oxygen requirements to one of their trials of the REGN-COV2 antibody cocktail.1 We note that this is a hold pending collection and analysis of further data, and that enrolment and randomisation of other patients with COVID-19 to this and other studies of the drug continues. 

‘Since REGN-COV2 is being studied in the RECOVERY trial, we have today discussed this announcement with Regeneron, with the UK Medicines & Healthcare products Regulatory Agency, and with the chair of the RECOVERY independent Data Monitoring Committee. The independent Data Monitoring Committee will review the latest data from the ongoing RECOVERY trial on Thursday 5 November. In the meantime, the RECOVERY trial will continue as planned.’ 

Professor Peter Horby and Professor Martin Landray, Co-leads, RECOVERY trial